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The oncogenic protein BCL-3 activates 
or represses gene transcription through binding 
with the NF-κB proteins p50 and p52 and is 
degraded through a phospho- and GSK3-
dependent pathway. However, the mechanisms 
underlying its degradation remain poorly 
understood. Yeast-two-hybrid analysis led to the 
identification of the proteasome subunit PSMB1 
as a BCL-3-associated protein. The binding of 
BCL-3 to PSMB1 is required for its degradation 
through the proteasome. Indeed, PSMB1-
depleted cells are defective in degrading 
polyubiquitinated BCL-3. The N-terminal part 
of BCL-3 includes lysines 13 and 26 required for 
the K48-linked polyubiquitination of BCL-3. 
Moreover, the E3 ligase FBW7 known to 
polyubiquitinate a variety of substrates 
phosphorylated by GSK3 is dispensable for 
BCL-3 degradation. Thus, our data defined an 
unique motif of BCL-3 that is needed for its 
recruitment to the proteasome and identified 
PSMB1 as a key protein required for the 
proteasome-mediated degradation of a nuclear 
and oncogenic IκB protein. 
 
BCL-3 is an nuclear protein that belongs to 
the IκB family and regulates gene transcription 
when bound to the NF-κB proteins p50 or p52 (1-
5). BCL-3 was originally identified through 
molecular cloning of the breakpoint of the t(14 ;19) 
chromosomal translocation found in a subset of 
human B-cell chronic lymphotic leukemias (6). 
This translocation triggers BCL-3 overexpression 
and consequently the deregulation of many target 
genes that may be involved in survival and cell 
proliferation (7). Since then, it has been shown that 
over-expressed BCL-3 contributes to the 
constitutive NF-κB activation seen in most solid 
and haematological malignancies (8). Indeed, BCL-
3 overexpression has been reported in multiple 
myelomas and subtypes of lymphomas, even in the 
absence of any t(14 ;19) chromosomal translocation 
(9-12). Interestingly, a deregulated BCL-3 
expression has also been reported in solid tumours 
such as breast cancers, nasopharyngeal and 
hepatocarcinomas, although the underlying 
mechanisms remain unclear (13-15). Familial 
cylindromatosis, a genetic disease characterized by 
benign tumours of hair-follicle keratinocytes 
(called cylindromas) results from loss-of-function 
mutations of CYLD, a deubiquitin ligase that 
specifically removes K63-linked polyubiquitin 
chains from various substrates, including BCL-3 
(16,17). As a result, the nuclear import of K63-
linked polyubiquitinated BCL-3 is enhanced and 
cell proliferation occurs through cyclin D1 gene 
induction (17). Therefore, multiple mechanisms that 
include chromosomal rearrangements or mutations 
of BCL-3-associated proteins ultimately trigger 
BCL-3 overexpression in the nucleus, a key event 
in BCL-3-mediated oncogenesis. This IκB protein 
has been formally defined as an oncoprotein based 
on the ability of BCL-3 expressing NIH3T3 cells to 
form foci and induce tumour growth in nude mice 
and also because bcl-3 transgenic mice developed 
lymphoproliferative disorders (18,19). 
To gain more insight on BCL-3 functions, 
we conducted yeast-two-hybrid analysis and 
defined the proteasome subunit PSMB1 as a BCL-
3-interacting protein that binds an unique sequence 
within the N-terminal domain of this oncoprotein. 
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This interaction is required for BCL-3 degradation, 
as evidenced by the stabilization of BCL-3 in 
PSMB1-depleted cells. Therefore, our data defined 
PSMB1 as a key protein required for the 
proteasome-dependent degradation of a nuclear IκB 
protein. 
 
Material and Methods 
 
Cell culture, biological reagents and treatments 
293, HeLa and Karpas cells were cultured as 
previously described (18).  
LiCl, TNFα and MG132 were purchased from 
Sigma (St-Louis, MO), Peprotech (Rocky Hill, NJ) 
and A&E Scientific (Marcq, Belgium), respectively. 
Polyclonal anti-HA, -Hsp90, -Myc, -BCL-3, -IκBα 
and monoclonal -α-tubulin, -Myc, -PML, and -
phospho-IκBα antibodies were purchased from 
Santa Cruz Biotechnologies (Santa Cruz, CA). 
Monoclonal anti-FLAG antibodies and beads were 
purchased from Sigma. Monoclonal anti-NBS1 
antibody was from BD Biosciences (Franklin 
Lakes, NJ). The polyclonal anti-PSMB1 antibody 
was from Biomol (Plymouth Meeting, PA). 
Polyclonal anti-p50 and monoclonal anti-p52 were 
from Millipore (Temecula, CA). GFP and PSMB1 
siRNAs were purchased from Dharmacon 
(Lafayette, CO). pMT2T p50, pMT2T p52, pMT2T 
BCL-3, pMT2T BCL-3 K13-26R, pMT2T BCL-3 
MTS, pMT2T BCL-3 ∆N (which lacks the first 112 
amino acids), FLAG-BCL-3, -∆N, -∆C, -∆N∆C and 
MTS were previously described, as were FLAG-
IκBα and FLAG-IκBα NLS MT (1,18,20).  FLAG-
BCL-3 ∆N10, -∆N30, -∆N43, -∆N67, -∆N92, and -
∆N120 constructs were generated by PCR whereas 
FLAG-BCL-3 ANK M1, -M12, -M123 and BCL-3 
5KR mutants were generated by mutagenesis. The 
BCL-3 ∆67-92 mutant that corresponds to the BCL-
3 ∆PSMB1 mutant was generated by subcloning the 
cDNA sequence corresponding to aa 1 to 66 and 
subsequently the domain corresposnding to aa 93 to 
the stop codon of BCL-3 into the pcDNA3-FLAG 
construct. FLAG-BCL-3 S394/398/419A was 
generated by mutagenesis using the FLAG-BCL-3 
MTS mutant as template. Myc-PSMB1 was 
generated by PCR amplification and subcloning 
into the pCMV-Myc vector (Invitrogen, Carlsbad, 
CA), using the PSMB1 cDNA clone pulled out 
from yeast-two-hybrid analysis as template. HA-
Ub, Ub K63R Myc were previously described (21). 
Myc-FBW1 was a gift from Dr. Nakayama 
(Department of Molecular and Cellular Pathology, 
Medical Institute of Bioregulation, Kyushu 
University, Japan) whereas Myc-FBW7 and Myc-
FBXW8 were generated by PCR using FLAG-
FBW7 (a gift from Dr. Clurman, Department of 
Medicine University of Washington School, Seattle, 
USA) and HA-FBXW8 (a gift from Dr. Jung, 
Institute für Pathologie, Bochum, Germany) as 
template, respectively. 
 
Yeast-two-hybrid, Immunoprecipitations and 
Immunofluorescences 
The bait was generated by subcloning the cDNA 
sequence of BCL-3 coding for the first 112 N-
terminal amino acids into the pGBKT7 vector 
(Clontech, Mountain View, CA) and yeast-two-
hybrid experiments were conducted as previously 
described (21), as were immunoprecipitations 
involving ectopically expressed proteins (18) as 




The N-terminal domain of BCL-3 harbours a 
nuclear localization signal dispensable for the 
interaction with the NF-κB proteins p50 and p52 
Both the N-terminal and the C-terminal 
domains of BCL-3 were previously defined as key 
regions for the regulation of the transactivation 
potential of this oncoprotein, yet the underlying 
mechanisms remain unclear (1). To learn more on 
the functions of these domains of BCL-3, we 
generated a variety of mutants lacking sequences 
either in the N- or C-terminal domain and first 
addressed their subcellular localization by 
immunofluorescence (Fig. 1A and 1B). We 
identified a nuclear localisation signal within the 
first 30 N-terminal amino acids. Indeed, whereas 
wild type (WT) BCL-3 was mainly but not 
exclusively located in the nucleus (Fig. 1B), 
removing the entire domain upstream of the ankyrin 
(“BCL-3 ∆N”) or the first 30 N-terminal amino 
acids of BCL-3 (“BCL-3 ∆N30”) localizes BCL-3 
mainly in the cytoplasm (Fig. 1B). While the N-
terminal domain was required for the nuclear 
localization of BCL-3, its C-terminal domain was 
dispensable as a mutant that lacks the entire C-
terminal domain downstream of the ankyrin repeats 
(“BCL-3 ∆C”) remained largely nuclear (Fig. 1B). 
Finally, removing both the N- and C-terminal 
domains of BCL-3 (“BCL-3 ∆N∆C”) led to an 
equal distribution of the resulting mutant in the 
cytoplasm and in the nucleus (Fig. 1B). Whereas 
the first 30 N-terminal amino acids were required 
for the nuclear localization of BCL-3, they were 
dispensable for the interaction with p50 or with p52 
as the BCL-3 ∆N30 mutant still bound both NF-κB 
 at UNIV DE LIEG
E-M
M









  Keutgens et al. 
 -3- 
proteins, as judged by co-immunoprecipitation 
analysis (Fig. 1C, top panels, lanes 5). Taken 
together, these data defined the N-terminal domain 
of BCL-3 as a key region for the nuclear 
localization of this oncoprotein. 
 
 
The binding of BCL-3 with p50 and p52 is 
required for its constitutive phosphorylation 
 Whereas the first 30 N-terminal domain of 
BCL-3, which harbours the nuclear localization 
signal, is dispensable for the interaction with the 
NF-κB proteins p50 and p52, the so-called ankyrin 
repeats are required for binding with those proteins 
(1).  
The sequence of BCL-3 spanning from 
amino acids 161 to 174 is highly similar to the one 
of IκBα spanning from amino acids 108 to 121 
(Fig. 2A). Interestingly, this second ankyrin repeat 
harbours the nuclear localization sequence (NLS) of 
IκBα and three point mutations within this domain 
indeed impaired IκBα nuclear localization as well 
as its interaction with p65 (23). To more precisely 
define the role of this highly conserved domain for 
the interaction with p50 and p52, we next generated 
BCL-3 mutants (referred to as “BCL-3 ANK M1”, -
M12, and -M123”) that harbour one, two, or three 
point mutations identical to those generated on the 
corresponding residues of the IκBα sequence (23) 
(Fig. 2A). We first determined whether these point 
mutations interfered with BCL-3 binding to p50 or 
p52 by co-immunoprecipitations in 293 cells. 
Whereas wild type (WT) BCL-3, and to a less 
extent BCL-3 ANK M1, associated with 
endogenous and ectopically expressed p50, both 
BCL-3 ANK M12 and -M123 failed to do so (Fig. 
2B, top panel, compare lanes 4 and 5 with lanes 6 
and 7). The same conclusion also applied for the 
ability of WT BCL-3 or BCL-3 mutants to interact 
with p52 (Fig. 2C, top panel, compare lane 5 with 
lanes 6 and 7). Of note, an IκBα mutant harbouring 
three mutations (“IκBα NLS MT”) did not bind as 
efficiently as wild type IκBα to p50 (Fig. 2B, top 
panel, compare lanes 8 and 9). Importantly, both 
BCL-3 ANK M12 and -M123 mutants were no 
longer constitutively phosphorylated, as judged by 
their migrating profile on an SDS PAGE gel (Fig. 
2B, middle panel, compare lane 4 with lanes 6 and 
7). Thus, our data suggest that binding of BCL-3 to 
p50 or p52 is required for the constitutive BCL-3 
phosphorylation. Point mutations within this 
ankyrin repeat also had consequences on BCL-3 
subcellular localization, as the BCL-3 ANK M123 
mutant equally distributed in the cytoplasm and in 
the nucleus while WT BCL-3 was mainly located in 
the nucleus (Fig. 2D). To further support the notion 
that the binding of BCL-3 to p50 or p52 is required 
for the GSK3-mediated phosphorylation of this 
oncogenic protein, we looked for these modified 
forms of BCL-3 in the cytoplasm and in the nucleus 
of Karpas cells left untreated or stimulated with 
LiCl, a GSK3 inhibitor. We noticed that BCL-3 was 
constitutively phosphorylated in a GSK3-dependent 
manner in both the nucleus and in the cytoplasm 
and was also bound to p52 in both cell 
compartments (Fig. 2E, top panels, lanes 2 to 4 and 
6 to 8). Indeed, the phosphorylated forms of BCL-3 
progressively disappeared upon LiCl treatment in 
the nucleus but also in the cytoplasm (Fig. 2E, third 
panel from the top, compare lanes 7 and 8 with lane 
5 as well as lanes 3 and 4 with lane 1, respectively). 
Therefore, these data suggest that the binding of 
BCL-3 to p50 or p52 is the key issue for its 
constitutive GSK3-mediated phosphorylation, 
rather than its nuclear localization. 
 
The degradative K48-linked polyubiquitination 
of BCL-3 requires the N-terminal lysine 13 and 
26 residues 
The critical role of the N-terminal domain 
of BCL-3 does not only result from the presence of 
this nuclear localization signal. Indeed, this domain 
is also targeted by post-translational modifications 
such as polyubiquitination (18). In fact, BCL-3 is 
subjected to both degradative (K48-linked) and non 
degradative (K63-linked) polyubiquitination but the 
signalling pathways involved in those modifications 
are poorly characterized (17,18). To prove that 
BCL-3 is indeed polyubiquitinated in vivo, we 
performed immunoprecipitation experiments in 
denaturing conditions in order to exclusively detect 
the polyubiquitinated forms of BCL-3 but not of the 
associated molecules. Polyubiquitinated adducts of 
BCL-3 were still detectable even in denaturing 
conditions that prevented its binding to the NF-κB 
protein p50 (Fig. 3A, compare lanes 2 and 6).  As 
expected, MG132 treatment facilitated the detection 
of polyubiquitinated adducts of BCL-3, even in 
denaturing conditions, further supporting the notion 
that the proteasome is required for BCL-3 
degradation (Fig. 3A and 3B, respectively, compare 
lanes 2 and 4). To learn more on the residues 
required for BCL-3 degradation, we next tested the 
K48-linked polyubiquitination of WT BCL-3 or the 
BCL-3 ∆N mutant in presence of MG132 and with 
an ubiquitin mutant that only makes K48 ubiquitin 
chains (“Ub K63R”). Removing the N-terminal 
domain of BCL-3 severely compromised the 
formation of K48-linked polyubiquitin chains on 
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this protein (Fig. 3C, top panel, compare lanes 2 
and 3). As this domain harbours two lysines 
(residues 13 and 26), we mutated both of them 
(“BCL-3 K13-26R”) and addressed the 
consequences on the K48-linked polyubiquitination 
of BCL-3 in presence of MG132. The detection of 
polyubiquitinated adducts on BCL-3 was severely 
impaired upon mutation of both lysine 13 and 26 
residues (Fig. 3C, top panel, compare lanes 2 and 
4). As expected, the mutations of all 5 lysine 
residues of BCL-3 (“BCL-3 5KR”) also impaired 
its K48-linked polyubiquitination (Fig. 3C, top 
panel, compare lanes 2 and 5). Interestingly, while 
MG132 did not modify BCL-3 localization, the 
mutant that lacks all lysine residues or the GSK3 
phosphorylation sites (“BCL-3 MTS”) (18) was 
mostly nuclear with bigger dots, as judged by 
immunofluorescence analysis, presumably because 
of an impaired degradation (Fig. 3D). Taken 
together, our data defined lysines 13 and 26 as key 
residues for the degradative K48-polyubiquitination 
of BCL-3. 
 
The N-terminal domain is required for the 
association of BCL-3 with the proteasome 
subunit PSMB1 
To further identify BCL-3-interacting 
partners involved in its K48-degradative 
polyubiquitination, yeast-two-hybrid experiments 
were conducted using the N-terminal domain of 
BCL-3 (amino acids 1 to 112) as bait (Fig. 4A). 
Positive clones included the co-repressor N-CoR, 
SUMO 1 (data not shown) as well as the entire 
coding sequence of PSMB1, a subunit of the 20S 
proteasome.  This latter interaction also occurred in 
mammalian cells as overexpressed FLAG-BCL-3 
associated with Myc-PSMB1, as judged by co-
immunoprecipitation experiments performed in 293 
cells (Fig. 4B, top panel, lane 4). The N-terminal 
domain of BCL-3 was confirmed to be required for 
binding to PSMB1 as the BCL-3 ∆N mutant failed 
to bind this proteasome subunit (Fig. 4C, top panel, 
lane 5). Interestingly, the BCL-3 products lacking 
the first 10 or 30 N-terminal amino acids (“BCL-3 
∆N10 and BCL-3 ∆N30”) still interacted with 
PSMB1 (Fig. 4D, top panel, lanes 3 and 4, 
respectively). Therefore, these results suggest that 
BCL-3 interacts with the proteasome via the N-
terminal domain between amino acids 31 and 112. 
We next performed immunofluorescence analysis in 
HeLa cells and observed that ectopically expressed 
BCL-3 colocalized with PSMB1 mainly but not 
exclusively in the nucleus (Fig. 4E, top panel on the 
right). Importantly, BCL-3 did not colocalize with 
the PML bodies in the nucleus (Fig. 4E, bottom 
panel on the right). Thus, the association of BCL-3 
with the proteasome subunit requires its N-terminal 
domain, mainly occurs in the nucleus and does not 
involve any shuttling into the PML bodies.  
 
PSMB1 is required for BCL-3 degradation 
 We next assessed the role of this proteasome 
subunit in the degradative polyubiquitination of 
BCL-3 through PSMB1-depleted 293 cells. Because 
IκBα is also degraded through the proteasome 
pathway upon TNFα stimulation (24), we first 
determined whether PSMB1 depletion impaired 
TNFα-mediated IκBα degradation. Whereas 
PSMB1 depletion did not interfere with TNFα-
mediated IκBα phosphorylation (Fig. 5A, second 
panel from the top, compare lanes 2 to 5 with lanes 
7 to 10), IκBα degradation triggered by this pro-
inflammatory cytokine was attenuated in PSMB1-
depleted 293 cells (Fig. 5A, top panel, compare 
lanes 3 and 4 with lanes 8 and 9). Thus, PSMB1 is 
required for the signal-induced IκBα degradation. 
The half-life of BCL-3 is also extended in PSMB1-
depleted Karpas cells (Fig. 5B, top panel, compare 
lanes 1 to 5 with lanes 6 to 10). In conclusion, 
PSMB1 is also required for BCL-3 degradation. A 
role for PSMB1 in BCL-3 degradation was further 
supported by the accumulation of BCL-3 
polyubiquitinated adducts upon PSMB1 depletion. 
Indeed, we transfected FLAG-BCL-3 and HA-Ub 
in siRNA GFP (negative control) or -PSMB1 293 
cells, isolated the nuclear proteins and looked for 
the BCL-3 polyubiquitinated forms in the anti-
FLAG immunoprecipitates. As a positive control, 
we pretreated the siRNA GFP cells with the 
proteasome inhibitor MG132. As expected, MG132 
treatment dramatically increased the amount of 
BCL-3 polyubiquitinated forms (Fig. 5C, top panel, 
compare lanes 2 and 4). Interestingly, an 
accumulation of BCL-3 polyubiquitinated forms 
was also detected upon PSMB1 depletion (Fig. 5C, 
top panel, compare lanes 2 and 6). Of note, this 
accumulation was not as dramatic as the one seen 
upon MG132 treatment (Fig. 5C, top panel, 
compare lanes 4 and 6). This may most likely be 
due to the partial PSMB1 loss of function as 
residual amounts of this proteasome subunit were 
still detectable in the siRNA PSMB1 cells (Fig. 5C, 
bottom panel, compare lanes 5 and 6 with lanes 1 to 
4). In conclusion, our data provide experimental 
evidence for a role of PSMB1 in BCL-3 
proteasomal degradation.  
As the degradation of BCL-3 through the 
proteasome is regulated by GSK3-mediated 
phosphorylation (18), we next explored whether 
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GSK3 inhibition by pharmacological means 
impaired the association of BCL-3 with PSMB1. To 
address this issue, 293 cells were transfected with 
FLAG-BCL-3 and Myc-PSMB1 and subsequently 
treated with LiCl, a GSK3 inhibitor. This inhibitor 
indeed impaired constitutive BCL-3 
phosphorylation (Fig. 5D, bottom panel, compare 
lanes 3 and 4) and also interfered with the binding 
of Myc-PSMB1 to FLAG-BCL-3 (Fig. 5D, top 
panel, compare lanes 3 and 4). This conclusion was 
also true when Myc-PSMB1 instead of FLAG-
BCL-3 was immunoprecipitated in unstimulated or 
LiCl-treated cells (Fig. 5E, top panel, compare lanes 
2 and 3, respectively). Thus, our results suggest that 
GSK3 phosphorylation triggers the recruitment of 
BCL-3 to the proteasome via binding to PSMB1. It 
is however important to note that the BCL-3 MTS 
mutant that lacks both GSK3 phosphorylation sites  
still bound PSMB1, although less efficiently than 
the wild type protein (Fig. 5E, top panel, compare 
lanes 4 and 2, respectively). Thus, BCL-3 may also 
be recruited to the proteasome through GSK3-
independent pathways. 
To further confirm that PSMB1 is required 
for BCL-3 degradation, we next generated a BCL-3 
mutant that specifically lacks the PSMB1-
interacting domain (“BCL-3 ∆PSMB1”) and 
subsequently addressed its half-life. We first 
deleted the first 43, 67, 92 or 120 N-terminal amino 
acids of BCL-3 and noticed that the BCL-3 ∆N67 
but not the ∆N92 mutant bound PSMB1 in co-
immunoprecipitation experiments in 293 cells (Fig. 
6A, top panel on the left, compare lanes 4 and 6, 
respectively). Of note all these BCL-3 mutants still 
bound the NF-κB protein p50 (Fig. 6A, top panel 
on the right, lanes 4 and 6).  The sequence of BCL-
3 between amino acids 68 and 92 harbours the 
PSMB1-interacting domain as the BCL-3 ∆67-92 
mutant (also named “BCL-3 ∆PSMB1”) failed to 
bind this proteasome subunit but still bound p50 
(Fig. 6A, top panels, lanes 5). Having generated the 
BCL-3 ∆PSMB1 mutant, we next addressed its 
half-life when expressed in 293 cells treated or not 
with cycloheximide. Whereas WT BCL-3 almost 
totally disappeared after 6 hours of CHX treatment, 
the BCL-3 ∆67-92 remained easily detectable at 
that time and its level of expression was very 
moderately decreased after 8 hours of CHX 
treatment, when compared to the levels of WT 
BCL-3 (Fig. 6B, compare lanes 6 to 10 with lanes 1 
to 5, respectively). A quantification of WT BCL-3 
or BCL-3 ∆67-92 levels confirmed this conclusion 
(Fig. 6B at the bottom). Therefore, our data strongly 
suggest that this BCL-3 ∆67-92 mutant has a 
prolonged half-life due to its inability to bind 
PSMB1. This last result thus defines PSMB1 as a 
key protein required for BCL-3 degradation. 
 
The E3 ligases FBW1, FBW7 and FBXW8 are 
dispensable for GSK3-mediated BCL-3 
degradation 
BCL-3 is degraded once phosphorylated by 
GSK3 on serines 394 and 398 located on its C-
terminal domain (18). Importantly, we identified a 
phosphodegron within this C-terminal domain of 
BCL-3 that is similar to the ones seen in other 
proteins known to be phosphorylated by GSK3 and 
polyubiquitinated by the E3 ligase FBW7 (Fig. 7A) 
(25-28). Therefore, we investigated whether BCL-3 
binds to this E3 ligase by co-immunoprecipitation 
analysis. As expected, FBW1, an E3 ligase required 
for TNFα-mediated IκBα degradation (29), 
efficiently bound this IκB protein in MG132 and 
TNFα-treated cells but failed to associate with 
BCL-3 (Fig. 7B, top panel, lanes 12 and 6, 
respectively). Moreover, FBW7 also failed to bind 
BCL-3, which indicates that this E3 ligase is 
dispensable for the GSK3-dependent pathway that 
leads to BCL-3 degradation. Of note, FBXW8, 
another E3 ligase, efficiently bound BCL-3 (Fig. 
7B, top panel, lane 8). This binding required the N-
terminal domain of BCL-3 as the BCL-3 ∆N mutant 
failed to bind this E3 ligase while the BCL-3 ∆C 
did (Fig. 7C, top panel, lanes 5 and 7, respectively). 
However, FBXW8 is also dispensable for BCL-3 
degradation through the GSK3-dependent pathway 
as a BCL-3 mutant that lacks both GSK3 
phosphorylation sites as well as serine 419 still 
bound this E3 ligase similarly to WT BCL-3 (Fig. 
7D, top panel, compare lanes 3 and 5). Taken 
together, our data indicate that BCL-3 binds to 
FBXW8, yet this binding is not required for the 





We report here the identification of the 
proteasome subunit PSMB1 as a BCL-3-associated 
protein that is critical for its degradation. This 
interaction requires the N-terminal domain of BCL-
3, which also harbours a NLS sequence as well as 
the lysine residues required for the K48-linked 
polyubiquitination of this nuclear IκB protein. Our 
data therefore defined the N-terminal domain of 
BCL-3 as a key element for its activity.  
The mechanisms underlying BCL-3 
degradation remained poorly characterized. We 
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previously identified a GSK3-dependent pathway 
that involves the phosphorylation of two C-terminal 
residues (18). We now show that BCL-3 is 
associated to the proteasome and interacts with the 
proteasome subunit PSMB1 once phosphorylated 
by GSK3. Interestingly, the GSK3-dependent 
pathway is negatively regulated by Akt (18), RAS 
as well as by PI3K (data not shown). Functional 
links, that appear to be cell-specific, were 
previously established between NF-κB and RAS. 
Although the NF-κB proteins p65 and c-Rel are 
dispensable for RAS-induced cellular 
transformation in NIH3T3 cells, they nevertheless 
potentiate RAS oncogenic potential (30). Indeed, 
some NF-κB-dependent genes such as Serpin B2 
and TSLP require p65 and/or c-Rel for their 
induction of expression by RAS (30). Of note, these 
genes are not induced by cytokines known to 
activate NF-κB (TNFα, IL-1β, …), which supports 
the idea that RAS induces the expression of some 
NF-κB-dependent genes while suppressing the 
ability of pro-inflammatory cytokines to activate 
NF-κB in fibroblasts (30,31). Another study 
reported that oncogenic RAS induces IKK 
activation and therefore IκBα degradation in liver 
epithelial cells (32). These studies, combined with 
our report, therefore suggest that multiple cross-
talks exist between oncoprotein RAS and NF-κB. 
The ability of RAS to stabilize BCL-3 defines a 
mechanism by which BCL-3 expression may be 
enhanced even in cases where the t(14 ;19) 
chromosomal translocation does not occur. Elevated 
levels of BCL-3 in the nucleus can also be the result 
of loss-of-function mutations targeting the 
deubiquitine ligase CYLD (17). Similarly, human 
papillomavirus (HPV)-positive cancers such as 
cervical as well as head and neck malignancies also 
have elevated levels of nuclear BCL-3 because the 
HPV-encoded E6 protein inactivates CYLD under 
hypoxic conditions (33). It is also tempting to 
speculate that loss-of-mutations of E3 ligases that 
target BCL-3 may ultimately causes the 
accumulation of this protein. These results thus 
considerably extent the pathological contexts that 
ultimately lead to BCL-3 over-expression in solid 
and haematological malignancies. 
 Multiple proteins whose GSK3-dependent 
phosphorylation triggers their subsequent 
degradation can be stabilized by RAS. Among those 
candidates is cyclin E whose degradation requires 
the E3 ligase FBW7 (34). The FBW7 substrates 
such as c-Myc, c-Jun, Notch1, cyclin D1 and cyclin 
E share a so-called Cdc4 phospho-degron (CPD) 
(35) that we actually found on BCL-3 (Fig. 7A). 
Yet, FBW7 does not bind phosphorylated BCL-3 
and the half-life of this IκB oncogenic protein is not 
enhanced in FBW7-depleted cells (data not shown). 
Importantly, BCL-3 binds to FBXW8, another E3 
ligase, through its N-terminal domain, yet this 
binding is not modulated by GSK3 
phosphorylation. Thus, the E3 ligase that 
polyubiquitinates BCL-3 upon phosphorylation by 
GSK3 remains unknown. Additional interactomic 
studies are currently in process in order to isolate 
the E3 ligase that specifically polyubiquitinates 
BCL-3 through the GSK3-dependent pathway. 
 BCL-3 may actually be degraded through 
more than one pathway. Indeed, we show here that 
a mutant that lacks the GSK3 phosphorylation sites 
is still, although more weakly, associated to the 
proteasome. Although this recruitment may not be 
exclusively required for BCL-3 degradation and 
may also be involved for the modulation of the 
transactivation potential of BCL-3, this indicate that 
other pathways, potentially phospho-independent, 
may also ultimately triggers BCL-3 degradation. It 
is also tempting to speculate that some loss-of-
function mutations targeting the E3 ligases required 
for BCL-3 degradation may also explain why the 
expression level of this oncoprotein is increased 
even in cases of malignancies where the 
translocation involving the bcl-3 gene is not 
observed. Future experimental strategies, mainly 
relying on interactomic studies, should shed more 
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Figure 1: The N-terminal domain of BCL-3 
harbours a nuclear localisation signal. A. On the 
left, schematic representation of the BCL-3 
constructs used in immunofluorescence analysis. The 
GSK3 phosphorylation sites (S394 and S398) as well 
as the lysine residues (13, 26, 266, 330 and 353) on 
BCL-3 are illustrated. On the right, anti-FLAG and 
α-tubulin (loading control) western blots using 
extracts from 293 cells transfected with the indicated 
expression plasmids. B. The N-terminal domain of 
BCL-3 is critical for its nuclear localization. HeLa 
cells were transfected with the indicated FLAG-
tagged expression plasmids and immunofluorescence 
studies were carried out using the anti-FLAG 
antibody. C. The 30 N-terminal amino acids of BCL-
3 are dispensable for the interaction with p50 and 
p52. 293 cells were transfected with the indicated 
expression plasmids and cell extracts were subjected 
to anti-HA (negative control), -FLAG or -BCL-3 
immunoprecipitations (IP) followed by anti-p50 or -
p100/p52 western blots (left and right top panels, 
respectively). Anti-p100/p52, -p50 and -BCL-3 
western blots were carried out with crude cell 
extracts (WCE) as well (bottom panels). 
 
Figure 2: BCL-3 binding to p50 or p52 is required 
for constitutive BCL-3 phosphorylation. A. 
Mutation of residues within the second ankyrin 
repeats of BCL-3. Both IκBα and BCL-3 are 
schematically illustrated. The NLS sequence within 
the second ankyrin repeat of IκBα is shown. The 
FLAG-IκBα NLS MT construct encodes a FLAG-
tagged IκBα protein harbouring three mutations 
within the NLS sequence (23). Single, double or 
triple mutants where the corresponding leucine and 
isoleucine residues within the second ankyrin repeats 
of BCL-3 were mutated into alanines, as indicated 
(“BCL-3 ANK M1, -M12 or M123”, respectively). B 
and C. The integrity of the second ankyrin repeat of 
BCL-3 is required for binding to p50 (B) or p52 (C). 
293 cells were transfected with the indicated 
expression plasmids and anti-HA (negative control) -
FLAG or -BCL-3 immunoprecipitations followed by 
anti-p50 (B) or p52 (C) western blot analysis were 
carried out (top panels). Cell extracts were also 
subjected to anti-FLAG, -p50 (B) and -p52 (C) 
western blot analysis (bottom panels). D. Mutations 
within the second ankyrin repeat alter the nuclear 
localization of BCL-3. HeLa cells were transfected 
with the indicated expression plasmids and the 
resulting cells were subjected to immunofluorescence 
analysis using the anti-FLAG antibody. E. 
Constitutive GSK3-mediated BCL-3 phosphorylation 
in the cytoplasm and in the nucleus of Karpas cells. 
Lymphoma-derived Karpas cells were left untreated  
(lanes 1, 2, 5 and 6) or stimulated with LiCl for the 
indicated periods of times (lanes 3, 4, 7 and 8) and 
cell extracts were subjected to anti-HA (negative 
control, lanes 1 and 5) or -BCL-3 
immunoprecipitations (lanes 2 to 4 and 6 to 8) 
followed by anti-p52/p100 western blot analysis (top 
panel). Crude cell extracts were subjected to anti-
p52/p100, -BCL-3, α-tubulin and -NBS1 western 
blots as well (bottom panels). 
 
Figure 3: The degradation of BCL-3 through the 
proteasome requires lysines 13 and 26. A and B. 
The proteasome is required for BCL-3 degradation. 
293 cells were transfected with the indicated 
expression plasmids and subsequently left untreated 
or stimulated for 2 hours with MG132 (20µM) the 
next day. Cell extracts (non-SDS lysis buffer (lanes 1 
to 4 (A)) or SDS lysis buffer (lanes 5 to 6 (A), and 
B)) were subjected to anti-FLAG 
immunoprecipitations followed by anti-HA (A and 
B) and -p50 (A) western blot analysis (top panels). 
Cell extracts were also subjected to anti-FLAG (A 
and B), -p50 (A) and -HA (A and B) western blot 
analysis (bottom panels). C. Critical roles of lysines 
13 and 26 for the K48-linked polyubiquitination of 
BCL-3. 293 cells were transfected with the indicated 
expression plasmids and subsequently treated with 
MG132 (20µM) for 4 hours. Cell extracts were 
subjected to anti-BCL-3 immunoprecipitations 
followed by anti-Myc western blot analysis (top 
panel). Anti-BCL-3 and -Myc western blots were 
also carried out on the crude cell extracts (bottom 
panels). D. Subcellular localization of wild type and 
BCL-3 mutants. HeLa cells were transfected with the 
indicated FLAG-tagged expression plasmid and 
immunofluorescence studies were carried out using 
the anti-FLAG antibody 
 
Figure 4: PSMB1 is a BCL-3-interacting protein. 
A. A schematic representation of both BCL-3 and the 
bait used for yeast-two-hybrid analyses. The GSK3 
phosphorylation sites (S394 and S398) as well as the 
lysine residues (13, 26, 266, 330 and 353) on BCL-3 
are illustrated. B to D. Ectopically expressed BCL-3 
and PSMB1 interact in mammalian cells through the 
N-terminal domain of BCL-3. 293 cells were 
transfected with the indicated expression plasmids. 
Cells were treated with MG132 (20µM) for 4 hours 
and anti-HA (B) (negative control) or -FLAG (B to 
D) immunoprecipitations followed by an anti-Myc 
western blot performed on the immunoprecipitates 
were carried out (top panels). Crude cell extracts 
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were subjected to anti-Myc and -FLAG western blots 
as well. E. PMSB1 and BCL-3 mainly colocalize in 
the nucleus. HeLa cells were transfected with FLAG-
BCL-3 and with Myc-PMSB1 and their localization 
were revealed through anti-FLAG and -Myc 
immunofluorescences, respectively. PML bodies 
were also visualized using the corresponding anti-
PML antibody. 
 
Figure 5: PSMB1-deficient cells show impaired 
BCL-3 degradation. A. PSMB1 depletion interferes 
with TNFα-mediated IκBα degradation but not its 
phosphorylation. 293 cells were transfected with a 
siRNA targeting either GFP (negative control, lanes 
1 to 5) or PSMB1 (lanes 6 to 10). Cells were 
subsequently left untreated (lanes 1 and 6) or 
stimulated with TNFα (100U/ml) for the indicated 
periods of time. Cell extracts were subjected to anti-
IκBα, -phospho-IκBα, -PSMB1 and α-tubulin, as 
indicated. B. BCL-3 half-life is increased upon 
PSMB1 depletion. Karpas cells were transfected with 
the indicated siRNA and subsequently left untreated 
(lanes 1 and 6) or stimulated with CHX (50µg/ml) 
(lanes 2 to 5 and 7 to 10) for the indicated periods of 
time. Anti-BCL-3, -PSMB1 and -Hsp90 (used for 
normalization purposes) western blots were carried 
out on the crude cell extracts, as indicated. C. K48-
linked polyubiquitinated forms of BCL-3 are 
accumulating upon MG132 treatment or PSMB1 
depletion. SiRNA GFP or PSMB1 293 cells were 
transfected with the indicated expression plasmids 
and subsequently left untreated (lanes 1, 2, 5 and 6) 
or stimulated with MG132 (20 µM) (lanes 3 and 4) 
for 4 hours. Cell extracts were subjected to anti-
FLAG immunoprecipitates followed by anti-HA 
western blot analysis (top panel). Anti-HA, -FLAG, -
NBS1 and -PSMB1 western blots were also carried 
out with the crude cell extracts (bottom panels). D 
and E. GSK3 enhances the association of BCL-3 to 
the proteasome. 293 cells were transfected with the 
indicated expression plasmids and subsequently left 
untreated (lanes 1 and 3 (D) and lanes 1, 2 and 4 (E)) 
or stimulated with LiCl (50mM) for 2 hours (lanes 2 
and 4 (D) and lane 3 (E)). Anti-FLAG (D) or -Myc 
(E) immunoprecipitates were subjected to anti-
PSMB1 (D) or BCL-3 (E) western blot analysis (top 
panels). Crude cell extracts were also subjected to 
anti-PSMB1 and -FLAG (D) and -BCL-3 (E) western 
blots (bottom panels). 
 
Figure 6: PSMB1 is required for BCL-3 
degradation. A.  Identification of the PSMB1-
binding domain on BCL-3. 293 cells were transfected 
with the indicated expression plasmids an anti-HA 
(negative control) or -FLAG immunoprecipitations 
followed by anti-Myc or -p50 western blots were 
carried out (top panels on the left and on the right, 
respectively). Crude cell extracts were subjected to 
anti-Myc, -FLAG and -p50 western blots, as 
indicated (bottom panels). B. Increased half-life of 
the BCL-3 mutant that fails to bind PSMB1 (“BCL-3 
∆67-92” also named “BCL-3 ∆PSMB1”). WT or the 
BCL-3 ∆PSMB1 mutants were transfected in 293 
cells and the resulting cells were left untreated or 
stimulated with cycloheximide (CHX) for the 
indicated periods of time. Anti-BCL-3 and Hsp90 
(loading control) were performed on the crude cell 
extracts. At the bottom, a quantification of WT BCL-
3 or BCL-3 ∆PSMB1 levels is shown in transfected 
293 cells. The signal intensity in unstimulated 293 
cells is set to 100% for both experimental conditions.   
 
Figure 7: FBW1, FBW7 and FBXW8 are 
dispensable for BCL-3 degradation through the 
GSK3-dependent pathway. A. Listing of the 
phosphodegrons seen in multiple FBW7 substrates 
and in BCL-3. The residues phosphorylated by GSK3 
are underlined. B to D. FBXW8 but not FBW1 and 
FBW7 bind BCL-3. 293 cells were transfected with 
the indicated expression constructs and subsequently 
left untreated (C and D) or stimulated with MG132 
and/or TNFα as indicated (B). Anti-FLAG 
immunoprecipitations followed by anti-Myc western 
blot analysis were performed (top panels). Crude cell 
extracts were subjected to anti-FLAG and -Myc 
western blots as well (bottom panels).  
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